Hexokinase

Hexokinase
Name	Hexokinase
Ec number	2.7.1.1

Hexokinase Hexokinase is an enzyme that catalyzes phosphorylation of hexoses, primarily converting glucose to glucose-6-phosphate, and serves as a gateway between extracellular Glucose transporter 1-mediated uptake and intracellular metabolic pathways such as Glycolysis and the Pentose phosphate pathway. It is studied across model organisms including Escherichia coli, Saccharomyces cerevisiae, Drosophila melanogaster, Mus musculus, and Homo sapiens and features in research at institutions like the Max Planck Society, National Institutes of Health, and European Molecular Biology Laboratory. Historical biochemical characterization connects to laboratories led by figures in enzymology affiliated with universities such as Harvard University, University of Cambridge, and Stanford University.

Introduction

Hexokinase catalyzes ATP-dependent phosphorylation of six-carbon sugars and was characterized through classical enzymology performed by researchers associated with Royal Society meetings, publications in journals affiliated with the American Chemical Society and Nature Research. Its activity integrates with pathways regulated by signaling nodes such as AMP-activated protein kinase and mTOR and is relevant to physiological contexts explored at centers like Mayo Clinic and Johns Hopkins University. Structural biology investigations were advanced at facilities such as the European Synchrotron Radiation Facility, Brookhaven National Laboratory, and Diamond Light Source.

Structure and Isozymes

Mammalian hexokinases exist as multiple isozymes (I–IV) encoded by genes studied in genomic projects at Human Genome Project consortia and annotated in databases maintained by the National Center for Biotechnology Information and Ensembl. Hexokinase I and II are ~100 kDa proteins composed of two homologous domains, whereas glucokinase (HK4) is monomeric and smaller; these observations derive from X-ray crystallography performed by groups at University of Oxford, Massachusetts Institute of Technology, and California Institute of Technology. Crystal structures resolved with ligands were deposited following standards set by the Protein Data Bank and analyzed in reviews from Cold Spring Harbor Laboratory Press. Isozyme expression patterns were mapped using transcriptomics platforms developed at Broad Institute and European Bioinformatics Institute.

Catalytic Mechanism and Regulation

The catalytic mechanism involves nucleophilic attack on ATP’s gamma phosphate, mechanistic proposals advanced in seminars at Max Planck Institute for Biophysical Chemistry and modeled using molecular dynamics packages from Schrödinger and GROMACS. Allosteric regulation differs among isozymes: glucokinase exhibits sigmoidal kinetics and regulatory interaction with glucokinase regulatory protein in hepatocytes, while hexokinase II is inhibited by its product and regulated by signaling through Protein kinase B and Glycogen synthase kinase 3. Post-translational modifications such as phosphorylation and acetylation were characterized in proteomics studies at EMBL-EBI and by consortia including the HUPO initiative. Kinetic parameters were first quantified in pioneering assays performed at laboratories affiliated with the Royal Institution and refined using high-throughput instrumentation from companies like Thermo Fisher Scientific.

Physiological Roles and Tissue Distribution

Isozyme distribution is tissue-specific: hexokinase I predominates in brain regions studied by neurobiology groups at Salk Institute and Karolinska Institutet, hexokinase II is abundant in skeletal muscle and cardiac tissue assessed at Cedars-Sinai Medical Center and UCLA, and glucokinase is primarily hepatic and pancreatic, characterized in clinical studies at Imperial College London and University College London. Hexokinase II couples to mitochondrial outer membrane proteins such as Voltage-dependent anion-selective channel protein 1 in contexts explored at Rockefeller University and influences apoptosis pathways elucidated in work from Dana-Farber Cancer Institute and Memorial Sloan Kettering Cancer Center. Its role in insulin secretion connects to research at Yale University School of Medicine and Columbia University Irving Medical Center.

Clinical Significance and Pathology

Hexokinase dysfunction contributes to metabolic disorders including forms of congenital hyperinsulinism linked to mutations characterized by clinical genetics teams at Great Ormond Street Hospital and Cleveland Clinic. Altered hexokinase expression is a hallmark of oncogenic metabolic reprogramming identified in studies at MD Anderson Cancer Center, Dana-Farber Cancer Institute, and research consortia like The Cancer Genome Atlas. Therapeutic strategies targeting hexokinase interactions with mitochondria have been explored in preclinical programs at pharmaceutical companies such as Pfizer and Novartis and in academic collaborations with University of Pennsylvania. Diagnostic use of altered hexokinase activity underlies imaging modalities employing Positron emission tomography tracers developed in collaboration with GE Healthcare and Siemens Healthineers.

Experimental Methods and Assays

Biochemical assays for hexokinase include spectrophotometric coupled-enzyme methods and radioisotope incorporation assays standardized in protocols distributed by centers like Cold Spring Harbor Laboratory and Addgene. Structural analysis uses cryo-electron microscopy at facilities including EMBL and small-angle X-ray scattering at beamlines operated by Argonne National Laboratory. Gene editing with CRISPR-Cas9 at centers such as Broad Institute and transcript profiling via RNA-Seq at Wellcome Sanger Institute facilitate functional studies. Proteomic interrogation employs mass spectrometers produced by Bruker and data analysis pipelines developed at European Molecular Biology Laboratory.

Category:Enzymes